170 related articles for article (PubMed ID: 31544207)
21. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
22. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Tseng CH
BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
[TBL] [Abstract][Full Text] [Related]
24. Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis.
Morgan CL; Inzucchi SE; Puelles J; Jenkins-Jones S; Currie CJ
Diabetes Obes Metab; 2018 Sep; 20(9):2140-2147. PubMed ID: 29732718
[TBL] [Abstract][Full Text] [Related]
25. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database.
Lo SC; Kornelius E; Liao PL; Huang JY; Yang YS; Huang CN
Diabetes Res Clin Pract; 2023 Jun; 200():110685. PubMed ID: 37100230
[TBL] [Abstract][Full Text] [Related]
26. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
Yen FS; Chiang JH; Pan CW; Lin BJ; Wei JC; Hsu CC
Diabetes Res Clin Pract; 2018 Jun; 140():279-287. PubMed ID: 29654814
[TBL] [Abstract][Full Text] [Related]
28. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
[TBL] [Abstract][Full Text] [Related]
29. Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.
Hsiao PJ; Wu KL; Chiu SH; Chan JS; Lin YF; Wu CZ; Wu CC; Kao S; Fang TC; Lin SH; Chen JS
Clin Exp Nephrol; 2017 Aug; 21(4):694-704. PubMed ID: 27599981
[TBL] [Abstract][Full Text] [Related]
30. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
31. Persons with type 2 diabetes and high insulin persistence were associated with a lower risk of mortality: A nationwide retrospective cohort study.
Yen FS; Wei JC; Liu JS; Hsu CC; Hwu CM
J Diabetes Investig; 2021 Feb; 12(2):146-154. PubMed ID: 32569417
[TBL] [Abstract][Full Text] [Related]
32. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
[TBL] [Abstract][Full Text] [Related]
33. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
[TBL] [Abstract][Full Text] [Related]
34. Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis.
Jong CB; Chen KY; Hsieh MY; Su FY; Wu CC; Voon WC; Hsieh IC; Shyu KG; Chong JT; Lin WS; Hsu CN; Ueng KC; Lai CL
Int J Cardiol; 2019 Sep; 291():152-157. PubMed ID: 30905518
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Ha J; Choi DW; Kim KY; Nam CM; Kim E
Cardiovasc Diabetol; 2021 Jul; 20(1):152. PubMed ID: 34315501
[TBL] [Abstract][Full Text] [Related]
36. Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
Yen CL; Wu CY; See LC; Li YJ; Tseng MH; Peng WS; Liu JR; Chen YC; Yen TH; Tian YC; Yang CW; Anderson GF; Yang HY
Diabetes Care; 2020 Oct; 43(10):e152-e153. PubMed ID: 32801131
[No Abstract] [Full Text] [Related]
37. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
38. Effects of pioglitazone on the incidence of dementia in patients with diabetes.
Chou PS; Ho BL; Yang YH
J Diabetes Complications; 2017 Jun; 31(6):1053-1057. PubMed ID: 28254448
[TBL] [Abstract][Full Text] [Related]
39. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Tseng CH
Int J Chron Obstruct Pulmon Dis; 2022; 17():285-295. PubMed ID: 35177899
[TBL] [Abstract][Full Text] [Related]
40. Association of Traditional Chinese Medicine Therapy and the Risk of Vascular Complications in Patients With Type II Diabetes Mellitus: A Nationwide, Retrospective, Taiwanese-Registry, Cohort Study.
Lee AL; Chen BC; Mou CH; Sun MF; Yen HR
Medicine (Baltimore); 2016 Jan; 95(3):e2536. PubMed ID: 26817897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
